Our data revealed that MAP3K7 deletion is often heterogeneous in prostate cancer and prevents TMPRSS2:ERG fusion, while TMPRSS2:ERG fusion allows MAP3K7 deletion. Here, TMPRSS2 is linked to prostate carcinoma.